TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33264808

Group type: EXPERIMENTAL
Intervention: ReliaTect Post‐Op Dressing (RELIATECT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard wound dressing (STANDARD)
Number of subjects: 160
Study: 32268807

Group type: EXPERIMENTAL
Intervention: Stress testing
Number of subjects: 9210

Group type: EXPERIMENTAL
Intervention: Computed Tomographic Angiography (CTA)
Number of subjects: 9210
Study: 36343740

Group type: EXPERIMENTAL
Intervention: 1.0mg vitamin K1 I.M.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.5mg vitamin K1 I.M.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.3mg vitamin K1 I.M.
Number of subjects: 75
Study: 33547573

Group type: EXPERIMENTAL
Intervention: Teleconference training
Number of subjects: 132

Group type: COMPARATOR
Intervention: In-person workshop training
Number of subjects: 132
Study: 33105353

Group type: EXPERIMENTAL
Intervention: β-Alanine (12 g/d for 14 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34155637

Group type: EXPERIMENTAL
Intervention: Behavior therapy (8 sessions)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait list control (8 sessions of behavior therapy after wait list)
Number of subjects: 53
Study: 34196442

Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg extended release)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 34953520

Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: BRII-196 plus BRII-198 (1000 mg each)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 33137103

Group type: EXPERIMENTAL
Intervention: IMARA program
Number of subjects: 199

Group type: COMPARATOR
Intervention: Health promotion control program
Number of subjects: 199
Study: 33580345

Group type: EXPERIMENTAL
Intervention: ACLR + LET
Number of subjects: 20

Group type: COMPARATOR
Intervention: ACLR
Number of subjects: 20
Study: 33319566

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (GL) 6 g/day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceratonia siliqua (CS) 6 g/day for 6 weeks
Number of subjects: 0
Study: 34644395

Group type: EXPERIMENTAL
Intervention: Post-treatment MRI showing 100% fibrotic fistula
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-treatment MRI MAGNIFI-CD index
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Degree of fibrosis at post-treatment MRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MAGNIFI-CD index at post-treatment MRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Youden cut-off point for MAGNIFI-CD index
Number of subjects: 50
Study: 32200813

Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly treatment
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Bevacizumab monthly treatment
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Monthly treatment
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: As-needed treatment
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Switching from monthly to as-needed treatment
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 1107
Study: 33461181

Group type: EXPERIMENTAL
Intervention: Laser-focused atomic deposition (LFAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme ultraviolet (EUV) interference lithography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cr grating manufactured by LFAD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cr grating and replicated grating (silicon grating)
Number of subjects: 0
Study: 33228583

Group type: EXPERIMENTAL
Intervention: Patients with psychotic disorders (n = 300)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Healthy controls (n = 51)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Patients with psychotic disorders
Number of subjects: 351

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 351
Study: 34047292

Group type: EXPERIMENTAL
Intervention: Electrophoresis using Depotphorese® device with calcium hydroxide plus copper paste (Cupral®), low current electric field (1.5 mA/min for 10 min).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without root canal preparation).
Number of subjects: 30
Study: 32998731

Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (OAT)
Number of subjects: 62
Study: 34895510

Group type: EXPERIMENTAL
Intervention: Delayed clamping (60 seconds or more)
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Immediate clamping (within 10 seconds)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Delayed clamping
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 1531
Study: 33823815

Group type: EXPERIMENTAL
Intervention: Oral intake of 300 ml carbohydrate solution (CH group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral intake of 300 ml pure water (PW group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fasting for 8 h before surgery (F group)
Number of subjects: 120
Study: 32125980

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) underwent nine sessions of repeated heat exposure at high temperatures (100 °C, 20% RH) for three weeks (HEHT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 29
Study: 36894666

Group type: EXPERIMENTAL
Intervention: Conventional cementation strategy (CRC group: adhesive system + resin cement) (Adper Single Bond + RelyX ARC; 3 M‐ESPE)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Self-adhesive cementation strategy (SRC group: self-adhesive resin cement; RelyX U100/U200; 3 M‐ESPE)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (CRC)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (SRC)
Number of subjects: 152
Study: 33277648

Group type: EXPERIMENTAL
Intervention: Tryptophan depleting drink
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 25
Study: 36345697

Group type: EXPERIMENTAL
Intervention: Hydroquinone 2% cream + 755-nm picosecond laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydroquinone 2% cream alone
Number of subjects: 20
Study: 33881335

Group type: EXPERIMENTAL
Intervention: Knowledge of obstetric danger signs
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Perceptions of need for antenatal care
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Perceptions of need for facility delivery
Number of subjects: 1624
Study: 34610971

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 and lurbinectedin 3.0-5.0 mg (escalation phase)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 (expansion cohort)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Doxorubicin and lurbinectedin (both cohorts)
Number of subjects: 34
Study: 32779375

Group type: EXPERIMENTAL
Intervention: Small-particle hyaluronic acid (SP-HA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Large-particle hyaluronic acid (LP-HA)
Number of subjects: 10
Study: 35945093

Group type: EXPERIMENTAL
Intervention: Anodal CRB‐tDCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham CRB‐tDCS
Number of subjects: 40
Study: 34429127

Group type: EXPERIMENTAL
Intervention: Aspirin, orally, 85-150 mg daily for 35 days after HA and 14 days after KA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH, enoxaparin), 40 mg, subcutaneously, daily within 24 hours postoperatively for 35 days after HA and 14 days after KA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study: 32776763

Group type: EXPERIMENTAL
Intervention: Physical therapy (superficial heat, transcutaneous electrical nerve stimulation, pulsed ultrasound)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (single intra-articular injection)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (three intra-articular injections)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20% dextrose (three intra-articular injections)
Number of subjects: 120
Study: 34706982

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33259790

Group type: EXPERIMENTAL
Intervention: Daytime eating schedule (0800 h-1900 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delayed eating schedule (1200 h-2300 h)
Number of subjects: 12
Study: 32733445

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 48
Study: 35640598

Group type: EXPERIMENTAL
Intervention: High Brazilian green propolis dose (H‐BGP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low Brazilian green propolis dose
Number of subjects: 18
Study: 32090117

Group type: EXPERIMENTAL
Intervention: Usual care with glucose fluctuation targeted intervention, targeting hemoglobin A1c (HbA1c) < 7%.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care focused on hemoglobin A1c (HbA1c) control, targeting A1c < 7%.
Number of subjects: 75
Study: 32105342

Group type: EXPERIMENTAL
Intervention: Total magnesium intake (diet + supplements)
Number of subjects: 104025

Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake
Number of subjects: 104025
Study: 35209777

Group type: EXPERIMENTAL
Intervention: Malnourished patients (n = 14)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Well-nourished patients (n = 44)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nutritional screening protocols MUST and NRS-2002
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: UICC classification and HPV status
Number of subjects: 58
Study: 34259406

Group type: EXPERIMENTAL
Intervention: Acupoint thread-embedding applied at Ganshu (BL 18), Pishu (BL 20), Shenshu (BL 23), Zusanli (ST 36), Guangming (GB 37), once every 2 weeks for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received comprehensive therapy of eye covering of intact side and family refined performance
Number of subjects: 60
Study: 36139151

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 92
Study: 34506608

Group type: EXPERIMENTAL
Intervention: Tocilizumab with or without corticosteroids
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Tocilizumab without corticosteroids
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard of care (SoC) only
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: SoC plus corticosteroid
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: SoC plus tocilizumab
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: SoC plus tocilizumab and corticosteroid
Number of subjects: 412
Study: 36170303

Group type: EXPERIMENTAL
Intervention: 5‐mm diameter healing abutment (group 1)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 6‐mm diameter healing abutment (group 2)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 7.5‐mm diameter healing abutment (group 3)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Provisional restoration (group 4)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Customized healing abutment (group 5)
Number of subjects: 246
Study: 33622047

Group type: EXPERIMENTAL
Intervention: Health care coverage
Number of subjects: 178
Study: 35791083

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 731

Group type: COMPARATOR
Intervention: Sacubitril/Valsartan
Number of subjects: 731
Study: 32649326

Group type: EXPERIMENTAL
Intervention: In-person interpreter
Number of subjects: 106

Group type: COMPARATOR
Intervention: Phone interpreter
Number of subjects: 106
Study: 32178655

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 200
Study: 33125902

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy with suture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coblation tonsillectomy without suture
Number of subjects: 0
Study: 32875638

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) membrane
Number of subjects: 117

Group type: COMPARATOR
Intervention: Native collagen membrane (BG)
Number of subjects: 117
Study: 34855690

Group type: EXPERIMENTAL
Intervention: Psychotropic medication use
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Attention-deficit/hyperactivity disorder (ADHD)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lower cognitive functioning
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Non-Hispanic White ethnicity
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 202
Study: 32015031

Group type: EXPERIMENTAL
Intervention: CSJ148 (combination of LJP538 and LJP539)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSJ148
Number of subjects: 0
Study: 616443500

Group type: EXPERIMENTAL
Intervention: Pregnant women (first, second, and third trimesters)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pregnant women (first trimester)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pregnant women (second trimester)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pregnant women (third trimester)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pregnant women (first two trimesters)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pregnant women (throughout gestation)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-pregnant women (control)
Number of subjects: 125
Study: 36070207

Group type: EXPERIMENTAL
Intervention: Prenatal stress lability
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline and mean stress
Number of subjects: 72
Study: 34155534

Group type: EXPERIMENTAL
Intervention: Reminder group (N=51)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: No-reminder group (N=51)
Number of subjects: 102
Study: 32988459

Group type: EXPERIMENTAL
Intervention: AES-scored multi-prompt writing screener
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: AES-scored screener with fewer prompts
Number of subjects: 559

Group type: COMPARATOR
Intervention: Screeners scored for word count
Number of subjects: 559
Study: 35781184

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrograms (VCUGs) recommended and obtained more frequently in patients <2-months-old
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Urinalysis and urine culture diagnostic criteria
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: UTI recurrence
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: fUTI recurrence
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 90-day readmission
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 90-day ED revisit
Number of subjects: 137
Study: 33667442

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 35012511

Group type: EXPERIMENTAL
Intervention: Educational intervention on vaccination
Number of subjects: 863
Study: 34301978

Group type: EXPERIMENTAL
Intervention: Deep-learning framework for analyzing fatty infiltration using automated region-based Otsu thresholding technique
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fatty infiltration measure using Otsu thresholding method
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Occupation ratio and fatty infiltration using Otsu thresholding
Number of subjects: 240
Study: 35964471

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study: 33108932

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 28
Study: 32554837

Group type: EXPERIMENTAL
Intervention: Qurs-e-Gulnar, 3 Qurs twice a day for 45 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diabeat®, 2 capsules twice a day for 45 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qurs-e-Gulnar
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diabeat®
Number of subjects: 40
Study: 35869349

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 452
Study: 34607885

Group type: EXPERIMENTAL
Intervention: Sitting during rounds
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standing during rounds
Number of subjects: 99
Study: 33202416

Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 16

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 16
Study: 35952629

Group type: EXPERIMENTAL
Intervention: HP + LFHD
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: HP + HFHD
Number of subjects: 438

Group type: COMPARATOR
Intervention: LFHD
Number of subjects: 438

Group type: COMPARATOR
Intervention: HFHD
Number of subjects: 438
Study: 33856418

Group type: EXPERIMENTAL
Intervention: 22-gene genomic classifier
Number of subjects: 0
Study: 32867965

Group type: EXPERIMENTAL
Intervention: FSE diet (basal diet + 100 mg/kg FSE)
Number of subjects: 192
Study: 35791025

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32892481

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (10 600 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50% trichloroacetic acid (TCA)
Number of subjects: 20
Study: 36332141

Group type: EXPERIMENTAL
Intervention: STEPS 1.1 module
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control module
Number of subjects: 15
Study: 34907421

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 32217275

Group type: EXPERIMENTAL
Intervention: Midfoot joint mobilization and home exercise program (HEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment and home exercise program (HEP)
Number of subjects: 0
Study: 35569003

Group type: EXPERIMENTAL
Intervention: Olanzapine plus probiotics
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Olanzapine plus probiotics and dietary fiber
Number of subjects: 150

Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 150
Study: 33479080

Group type: EXPERIMENTAL
Intervention: Hub-and-spoke thrombectomy service in routine UK 24/7 clinical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients accepted for transfer to the thrombectomy centre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombectomy cases performed outside of standard working hours
Number of subjects: 0
Study: 33726537

Group type: EXPERIMENTAL
Intervention: Topical Nepafenac
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no prophylactic treatment)
Number of subjects: 38
Study: 34528220

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 µg twice daily
Number of subjects: 3589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3589
Study: 36332827

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg/70 kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Active placebo (50 mg diphenhydramine)
Number of subjects: 96
Study: 33106970

Group type: EXPERIMENTAL
Intervention: Tube current of 13 mA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tube current of 10 mA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tube current of 7 mA
Number of subjects: 30
Study: 32513277

Group type: EXPERIMENTAL
Intervention: Household drinking water disinfection by chlorination (1.2% sodium hypochlorite)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (usual habits of water collection and storage)
Number of subjects: 405
Study: 35794485

Group type: EXPERIMENTAL
Intervention: Synergistic mindsets intervention (self-administered online training module)
Number of subjects: 3410

Group type: EXPERIMENTAL
Intervention: Synergistic mindsets intervention
Number of subjects: 3410
Study: 33844587

Group type: EXPERIMENTAL
Intervention: Device-facilitated lingual exercise regimen
Number of subjects: 0
Study: 36042425

Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (WATs) with a mobile application for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Digital support in OA care
Number of subjects: 18
Study: 34570054

Group type: EXPERIMENTAL
Intervention: Individual feedback about bedtime, wake time, and sleep duration
Number of subjects: 15

Group type: COMPARATOR
Intervention: No individual feedback
Number of subjects: 15
Study: 36399969

Group type: EXPERIMENTAL
Intervention: BNT162b2 (30 μg)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Half-dose mRNA-1273 (50 μg)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 μg)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 (15 μg)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: All booster vaccines
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: mRNA vaccines
Number of subjects: 340
Study: 32172626

Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Community outings
Number of subjects: 322
Study: 32273122

Group type: EXPERIMENTAL
Intervention: Stick™ resin treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ethylene glycol + triazabicyclodecene treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (0s)
Number of subjects: 100
Study: 34519555

Group type: EXPERIMENTAL
Intervention: Nurse-led education program for stroke patients, 20-week duration
Number of subjects: 92
Study: 34949227

Group type: EXPERIMENTAL
Intervention: Diabetic yoga protocol (DYP)
Number of subjects: 184
Study: 34244703

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 3312

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 3312